IPS Could Minimize GI Effects in Treating Iron Deficiency

Review summarizes pharmacokinetic and clinical data on iron protein succinylate across patients with iron deficiency and iron deficiency anemia.

Category	Detail
Condition	Iron Deficiency and Iron Deficiency Anemia
Key Mechanisms	Iron protein succinylate (IPS) is a ferric complex that improves iron absorption and reduces gastrointestinal side effects.
Target Population	Patients with iron deficiency, including those with inflammatory conditions, pregnant women, blood donors, and individuals with chronic diseases.
Care Setting	Outpatient and clinical settings for managing iron deficiency.

IPS shows comparable or superior hematologic outcomes to conventional oral iron.
IPS has a higher clinical response rate (79% vs 68%) and fewer adverse events (12% vs 26%).
IPS improves iron absorption significantly compared to ferrous sulfate.
Alternate-day dosing may enhance iron absorption and tolerability.
Patients with inflammatory conditions may still require intravenous iron therapy.

Consider IPS as a first-line treatment for patients with iron deficiency and poor tolerability to oral iron.

Regularly monitor hemoglobin and ferritin levels during treatment to assess response.

Monitor for gastrointestinal side effects, particularly in patients with a history of GI issues.

Patients with iron deficiency, including those with chronic inflammatory conditions, pregnant women, and blood donors.

IPS may offer improved tolerability and effectiveness compared to traditional oral iron supplements.

Utilize IPS for patients who experience gastrointestinal side effects from conventional iron supplements.
Implement alternate-day dosing strategies to enhance iron absorption.
Evaluate the need for intravenous iron therapy in patients with inflammatory conditions.